Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Breast Neoplasms

Neoplasm Metastasis

Neoplastic Processes

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Taxane

Antimitotic Agents

Eribulin Dosage: 1.4 mg/m2 Route of administration: IV bolus Schedule of cycle: D1 and D8 every 21 days

Eribulina

Antonio Llombart, MD

Multicentre, prospective, non-controlled phase II clinical trial to evaluate the efficacy and tolerability of first line single agent Eribulin in patients with HER2-negative metastatic breast carcinoma previously exposed to taxanes for early stage.

The primary objective of the study is to determine the median time to progression achieved with Eribulin. Other secondary objectives will be; overall response rate, clinical benefit rate, time to treatment progression, duration of response and toxicity profile.

Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment

A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes

MedSIR

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment	NCT02061085	Breast Neoplasm Metastasis	Eribulina	18 Years -	MedSIR
Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment	NCT02061085	Breast Neoplasm Metastasis	Eribulina	18 Years -	MedSIR

Spots Global Cancer Trial Database for furans, quetones